272 Results

People

  1. Motzer
    Motzer
  2. Scher
    Scher
  3. Horwitz
    Horwitz
  4. Bajorin
    Bajorin
  5. Bosl
    Bosl
  6. Sheinfeld
    Sheinfeld
  7. Palomba
    Palomba
  8. Perales
    Perales
  9. Salles
    Salles
  10. Mazumdar
    Mazumdar

Groups

  1. Department of Medicine (159)
  2. Solid Tumor Oncology Division (90)
  3. Hematologic Malignancies, Division of (77)
  4. Center for Hematologic Malignancies (73)
  5. Genitourinary Oncology Service (53)
  6. Survivorship Research (43)
  7. Surgery (41)
  8. Lymphoma (39)
  9. GSK Faculty (37)
  10. Epidemiology and Biostatistics (28)
  1. "lactate dehydrogenase"
Formats
  1. Journal Article (247)
  2. Review (9)
  3. Research Letter (8)
  4. Conference Paper (3)
  5. Editorial (3)
  6. Correspondence (1)
  7. Guidelines (1)
Groups
  1. Department of Medicine (159)
  2. Solid Tumor Oncology Division (90)
  3. Hematologic Malignancies, Division of (77)
  4. Center for Hematologic Malignancies (73)
  5. Genitourinary Oncology Service (53)
  6. Survivorship Research (43)

More Groups

People
  1. Robert Motzer (24)
  2. Howard Scher (16)
  3. Steven Horwitz (14)
  4. George Bosl (13)
  5. Dean Bajorin (12)
  6. Joel Sheinfeld (10)

More People

Years
  1. 2025 (16)
  2. 2024 (26)
  3. 2023 (16)
  4. 2022 (13)
  5. 2021 (7)
  6. 2020 (12)

More Years

Publications
  1. Journal of Clinical Oncology (23)
  2. Cancer (20)
  3. Haematologica (9)
  4. Blood (7)
  5. Leukemia and Lymphoma (7)
  6. Annals of Surgical Oncology (6)

More Publications

Publishers
  1. Wiley Blackwell (31)
  2. Elsevier Inc. (28)
  3. American Society of Clinical Oncology (24)
  4. Nature Publishing Group (19)
  5. Elsevier Science, Inc. (17)
  6. Springer (14)

More Publishers

Results (272)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • High serum LDH and liver metastases are the dominant predictors of primary cancer resistance to anti-PD(L)1 immunotherapy
    Journal Article

    Dercle, L.; Ammari, S.; Roblin, E.; Bigorgne, A.; Champiat, S.; Taihi, L.; Plaian, A.; Hans, S.; Lakiss, S.; Tselikas, L.; more...
    European Journal of Cancer (2022)

    Fulltext@MSK | Save
  • Patterns of use, outcomes, and resource utilization among recipients of commercial axicabtagene ciloleucel and tisagenlecleucel for relapsed/refractory aggressive B cell lymphomas
    Journal Article

    Riedell, P. A.; Hwang, W. T.; Nastoupil, L. J.; Pennisi, M.; McGuirk, J. P.; Maziarz, R. T.; Bachanova, V.; Oluwole, O. O.; Brower, J.; Flores, O. A.; more...
    Transplantation and Cellular Therapy (2022)

    Fulltext@MSK | Save
  • Benefit and toxicity of programmed death-1 blockade vary by ethnicity in patients with advanced melanoma: An international multicentre observational study*
    Journal Article

    Bai, X.; Shoushtari, A. N.; Betof Warner, A.; Si, L.; Tang, B.; Cui, C.; Yang, X.; Wei, X.; Quach, H. T.; Cann, C. G.; more...
    British Journal of Dermatology (2022)

    Fulltext@MSK | Save
  • Single-agent anti-PD-1 or combined with ipilimumab in patients with mucosal melanoma: An international, retrospective, cohort study
    Journal Article

    Dimitriou, F.; Namikawa, K.; Reijers, I. L. M.; Buchbinder, E. I.; Soon, J. A.; Zaremba, A.; Teterycz, P.; Mooradian, M. J.; Armstrong, E.; Nakamura, Y.; more...
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • Demographics, outcomes, and risk factors for patients with sarcoma and COVID-19: A CCC19-registry based retrospective cohort study
    Journal Article

    Wagner, M. J.; Hennessy, C.; Beeghly, A.; French, B.; Shah, D. P.; Croessmann, S.; Vilar-Compte, D.; Ruiz-Garcia, E.; Ingham, M.; Schwartz, G. K.; more...
    Cancers (2022)

    Fulltext@MSK | Save
  • Simplified graded infusion strategy for mitigation of oxaliplatin hypersensitivity
    Journal Article

    Alonso Martinez, S.; Segal, N. H.; Cercek, A.; Yaeger, R.; Stadler, Z.; Kemeny, N. E.; Nusrat, M.; Shahrokni, A.; Connell, L.; Saltz, L. B.
    Clinical Colorectal Cancer (2022)

    Fulltext@MSK | Save
  • Highly favorable outcomes with salvage radiation therapy and autologous hematopoietic cell transplantation in relapsed and refractory DLBCL patients with minimal to no response to salvage chemotherapy
    Research Letter

    Yang, J. C.; Scordo, M.; Chau, K. W.; Sauter, C. S.; Yahalom, J.
    Bone Marrow Transplantation (2022)

    Fulltext@MSK | Save
  • Gene expression profiling in multiple myeloma: Redefining the paradigm of risk-adapted treatment
    Review

    Cerchione, C.; Usmani, S. Z.; Stewart, A. K.; Kaiser, M.; Rasche, L.; Kortüm, M.; Mateos, M. V.; Spencer, A.; Sonneveld, P.; Anderson, K. C.
    Frontiers in Oncology (2022)

    Fulltext@MSK | Save
  • Autologous transplant vs chimeric antigen receptor T-cell therapy for relapsed DLBCL in partial remission
    Journal Article

    Shadman, M.; Pasquini, M.; Ahn, K. W.; Chen, Y.; Turtle, C. J.; Hematti, P.; Cohen, J. B.; Khimani, F.; Ganguly, S.; Merryman, R. W.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Prospects in the management of patients with follicular lymphoma beyond first-line therapy
    Journal Article

    Qualls, D.; Salles, G.
    Haematologica (2022)

    Fulltext@MSK | Save